Generation of functionally mature dendritic cells from elutriated monocytes using polyinosinic : polycytidylic acid and soluble CD40 ligand for clinical application
- PMID: 18782327
- PMCID: PMC2633224
- DOI: 10.1111/j.1365-2249.2008.03757.x
Generation of functionally mature dendritic cells from elutriated monocytes using polyinosinic : polycytidylic acid and soluble CD40 ligand for clinical application
Abstract
Despite the increasing use of dendritic cell (DC) vaccination in clinical trials, optimal conditions for the generation of functionally mature DCs remain to be established. The current standard DC maturation protocol for clinical trials has been used as an inflammatory cytokine cocktail [tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and prostaglandin E(2)], but this cocktail induced insufficient maturation of DCs derived from elutriated monocytes when cultured in X-VIVO 15. The aim of this study was to define effective combinations of stimulators for generating functionally mature DCs from elutriated monocytes under current good manufacturing practice conditions. We compared the functional capacity of DCs in response to all possible pairwise combinations of four different classes of stimuli: TNF-alpha, peptidoglycan, polyinosinic : polycytidylic acid [poly(I:C)] and soluble CD40 ligand (CD40L). Maturation status of DCs stimulated with combination of four stimuli was similar to that of the cytokine cocktail as assessed by the cell surface phenotype. However, only the combination of poly(I:C) + CD40L induced complete functional activation of the whole DC population, assessing IL-12p70 production, allostimulatory activity, migratory response to CCL19 and T helper 1-polarizing capacity. Thus, the protocol based on the combination of poly(I:C) and CD40L is more effective for the induction of clinical-grade DCs from elutriated monocytes than the standard cytokine cocktail.
Figures





Similar articles
-
Tumor necrosis factor-α promotes survival and phenotypic maturation of poly(I:C)-treated dendritic cells but impairs their Th1 and Th17 polarizing capability.Cytotherapy. 2015 May;17(5):633-46. doi: 10.1016/j.jcyt.2014.11.006. Epub 2015 Jan 2. Cytotherapy. 2015. PMID: 25559144
-
Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.Vaccine. 2008 Jun 2;26(23):2824-32. doi: 10.1016/j.vaccine.2008.03.054. Epub 2008 Apr 11. Vaccine. 2008. PMID: 18450338
-
The influence of CD40 ligation and interferon-gamma on functional properties of human monocyte-derived dendritic cells activated with polyinosinic-polycytidylic acid.Vojnosanit Pregl. 2011 Apr;68(4):301-8. doi: 10.2298/vsp1104301d. Vojnosanit Pregl. 2011. PMID: 21627015
-
IL-1 beta enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): a mechanism for T cell-independent DC activation.J Immunol. 2002 Jan 15;168(2):713-22. doi: 10.4049/jimmunol.168.2.713. J Immunol. 2002. PMID: 11777965 Clinical Trial.
-
Cytokines in the generation and maturation of dendritic cells: recent advances.Eur Cytokine Netw. 2002 Apr-Jun;13(2):186-99. Eur Cytokine Netw. 2002. PMID: 12101074 Review.
Cited by
-
Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation.PLoS Biol. 2014 Jan;12(1):e1001759. doi: 10.1371/journal.pbio.1001759. Epub 2014 Jan 7. PLoS Biol. 2014. PMID: 24409099 Free PMC article.
-
Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy.J Cell Mol Med. 2012 Nov;16(11):2827-37. doi: 10.1111/j.1582-4934.2012.01614.x. J Cell Mol Med. 2012. PMID: 22882679 Free PMC article.
-
Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials.J Transl Med. 2011 Dec 30;9:223. doi: 10.1186/1479-5876-9-223. J Transl Med. 2011. PMID: 22208910 Free PMC article.
-
Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect.Int J Mol Sci. 2021 Nov 15;22(22):12339. doi: 10.3390/ijms222212339. Int J Mol Sci. 2021. PMID: 34830221 Free PMC article. Review.
-
p21 Restricts HIV-1 in Monocyte-Derived Dendritic Cells through the Reduction of Deoxynucleoside Triphosphate Biosynthesis and Regulation of SAMHD1 Antiviral Activity.J Virol. 2017 Nov 14;91(23):e01324-17. doi: 10.1128/JVI.01324-17. Print 2017 Dec 1. J Virol. 2017. PMID: 28931685 Free PMC article.
References
-
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52. - PubMed
-
- Osada T, Clay TM, Woo CY, Morse MA, Lyerly HK. Dendritic cell-based immunotherapy. Int Rev Immunol. 2006;25:377–413. - PubMed
-
- Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Ann Rev Immunol. 2000;18:245–73. - PubMed
-
- O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 2004;104:2235–46. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials